Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Non-cash Items (2018 - 2025)

Crinetics Pharmaceuticals has reported Non-cash Items over the past 8 years, most recently at $7.5 million for Q2 2025.

  • For Q2 2025, Non-cash Items fell 97.42% year-over-year to $7.5 million; the TTM value through Jun 2025 reached $7.5 million, down 97.42%, while the annual FY2024 figure was $6.5 million, 23.27% up from the prior year.
  • Non-cash Items for Q2 2025 was $7.5 million at Crinetics Pharmaceuticals, down from $136.4 million in the prior quarter.
  • Over five years, Non-cash Items peaked at $4.1 billion in Q4 2022 and troughed at $2172.0 in Q1 2021.
  • A 5-year average of $274.2 million and a median of $10.9 million in 2023 define the central range for Non-cash Items.
  • On a YoY basis, Non-cash Items climbed as much as 2526690.75% in 2021 and fell as far as 99.99% in 2021.
  • Year by year, Non-cash Items stood at $80.9 million in 2021, then skyrocketed by 4995.56% to $4.1 billion in 2022, then tumbled by 99.87% to $5.3 million in 2023, then grew by 23.27% to $6.5 million in 2024, then grew by 15.0% to $7.5 million in 2025.
  • Business Quant data shows Non-cash Items for CRNX at $7.5 million in Q2 2025, $136.4 million in Q1 2025, and $6.5 million in Q4 2024.